{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:27:42Z","timestamp":1790267262086,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.clinthera.2015.05.510","type":"journal-article","created":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T17:30:08Z","timestamp":1435685408000},"page":"1604-1616","source":"Crossref","is-referenced-by-count":60,"title":["Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?"],"prefix":"10.1016","volume":"37","author":[{"given":"Megan J.","family":"Ehret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Chamberlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.05.510_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jalz.2012.02.001","article-title":"Alzheimer\u2019s disease facts and figures","volume":"8","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clinthera.2015.05.510_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","article-title":"Epidemiology of Alzheimer disease","volume":"7","author":"Reitz","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.clinthera.2015.05.510_bib3","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1259\/bjr\/97295129","article-title":"Positron emission tomography imaging in dementia","volume":"80","author":"Herholz","year":"2007","journal-title":"Br J Radiol"},{"key":"10.1016\/j.clinthera.2015.05.510_bib4","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/S0140-6736(96)09124-6","article-title":"Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer\u2019s disease","volume":"349","author":"Iyo","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.05.510_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neulet.2005.01.031","article-title":"Cognitive correlates of alterations in acetylcholinesterase in Alzheimer\u2019s disease","volume":"380","author":"Bohnen","year":"2005","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.clinthera.2015.05.510_bib6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1126\/science.278.5337.412","article-title":"Life and death of neurons in the aging brain","volume":"278","author":"Morrison","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2015.05.510_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0197-4580(99)00035-4","article-title":"Phenotypic downregulation of glutamate receptor subunit GluR1 in Alzheimer\u2019s disease","volume":"20","author":"Wakabayashi","year":"1999","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.clinthera.2015.05.510_bib8","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/ern.12.124","article-title":"Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer\u2019s disease","volume":"12","author":"Francis","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.clinthera.2015.05.510_bib9","unstructured":"Aricept (donepezil hydrochloride) [package insert]. Teaneck, NJ: Eisai, Revised 2013"},{"key":"10.1016\/j.clinthera.2015.05.510_bib10","unstructured":"Exelon (rivastigmine tartrate) [package insert]. East Hanover, NJ: Novartis, Revised 2013"},{"key":"10.1016\/j.clinthera.2015.05.510_bib11","unstructured":"Razadyne ER\/Razadyne (galantamine hydrobromine) [package insert]. Titusville, NJ: Ortho-McNeil Neurologics, Revised 2013"},{"key":"10.1016\/j.clinthera.2015.05.510_bib12","unstructured":"Namenda (memantine hydrochloride) [package insert]. St. Louis, MO: Forest Pharmaceutica, Inc, Revised 2013."},{"key":"10.1016\/j.clinthera.2015.05.510_bib13","article-title":"(memantine hydrochloride) [package insert]. St. Louis, MO: Forest Pharmaceutica, Inc","author":"Namenda","year":"2013","journal-title":"Revised"},{"key":"10.1016\/j.clinthera.2015.05.510_bib14","unstructured":"Actavis and Adamas Announce FDA Approval of Namzaric, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride. http:\/\/www.actavis.com\/news\/news\/thomson-reuters\/actavis-and-adamas-announce-fda-approval-of-namzar. Accessed March 22, 2015."},{"key":"10.1016\/j.clinthera.2015.05.510_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jaging.2011.03.002","article-title":"The controversial promises of cholinesterase inhibitors for Alzheimer\u2019s disease and related dementias: a qualitative study of caregivers\u2019 experiences","volume":"25","author":"Smith","year":"2011","journal-title":"J Aging Stud"},{"key":"10.1016\/j.clinthera.2015.05.510_bib16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1532-5415.2004.52230_1.x","article-title":"Another advertisement for donepezil","volume":"52","author":"Finucane","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2015.05.510_bib17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1532-5415.2004.52230_2.x","article-title":"Donepezil\u2019s effects remain uncertain","volume":"52","author":"Royall","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2015.05.510_bib18","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1532-5415.2004.52230_3.x","article-title":"Donepezil delay to nursing home placement study is flawed","volume":"52","author":"Karawish","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2015.05.510_bib19","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/archneur.63.7.1036-a","article-title":"Open-label extension studies and misinformation","volume":"63","author":"Schneider","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2015.05.510_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1017\/S1041610211002389","article-title":"Could cholinesterase inhibitors be harmful over the long term?","volume":"24","author":"Schneider","year":"2012","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.clinthera.2015.05.510_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clin Trials"},{"key":"10.1016\/j.clinthera.2015.05.510_bib22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/WNL.57.3.481","article-title":"A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients","volume":"57","author":"Mohs","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2015.05.510_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1212\/WNL.57.3.489","article-title":"A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD","volume":"57","author":"Winblad","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2015.05.510_bib24","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezil treatment in 565 patients with Alzheimer\u2019s disease (AD2000): randomized double-blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.05.510_bib25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3346\/jkms.2008.23.1.10","article-title":"for the Korean Galantamine Study Group. Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer\u2019s disease in a Korean population: a 52-week prospective study","volume":"23","author":"Suh","year":"2008","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.clinthera.2015.05.510_bib26","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/070674371405901202","article-title":"Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease","volume":"59","author":"Hogan","year":"2014","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.clinthera.2015.05.510_bib27","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","article-title":"Donepezil in patients with severe Alzheimer\u2019s disease: double-blind, parallel-group, placebo-controlled study","volume":"367","author":"Winblad","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.05.510_bib28","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.clinthera.2010.06.019","article-title":"Effectiveness and tolerability of high-dose (23 mg\/d) versus standard dose (10 mg\/d) donepezil in moderate to severe Alzheimer\u2019s disease: a 24-week, randomized, double-blind study","volume":"32","author":"Farlow","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2015.05.510_bib29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2318-13-56","article-title":"Evaluating the cognitive effects of donepezil 23 mg\/d in moderate and severe Alzheimer\u2019s disease: analysis of effects of baseline features on treatment response","volume":"13","author":"Sabbagh","year":"2013","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.clinthera.2015.05.510_bib30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000338236","article-title":"Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer\u2019s disease: a subgroup analysis in patients already taking or not taking concomitant memantine","volume":"33","author":"Doody","year":"2012","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.clinthera.2015.05.510_bib31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/cns.12158","article-title":"A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg\/24 h versus 4.6 mg\/24 h in severe Alzheimer\u2019s dementia","volume":"19","author":"Farlow","year":"2013","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.clinthera.2015.05.510_bib32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(08)70261-8","article-title":"Safety and efficacy of galantamine (Reminyl) in severe Alzheimer\u2019s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial","volume":"8","author":"Burns","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2015.05.510_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-2011-110134","article-title":"Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer\u2019s disease: a randomized, double blind, placebo controlled withdrawal trial","volume":"26","author":"Scarpini","year":"2011","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.clinthera.2015.05.510_bib34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40263-013-0077-7","article-title":"The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer\u2019s disease taking cholinesterase inhibitors","volume":"27","author":"Grossberg","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2015.05.510_bib35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease","volume":"366","author":"Howard","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.05.510_bib36","unstructured":"Center for Drug Evaluation and Research, US Food and Drug Administration. Sustained Release Aricept in Administrative Documents & Correspondence 02256Orig1s000Admincorres.pdf [memorandum of meeting minutes, March 19, 2007, IND 35,974]. www.accessdata.fda.gov\/drugsatfda_doc\/nda\/2010\/02256Orig1s000Admincorres.pdf. Accessed April 15, 2015."},{"key":"10.1016\/j.clinthera.2015.05.510_bib37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3810\/pgm.2012.11.2589","article-title":"Higher dose (23mg\/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer\u2019s disease","volume":"124","author":"Christensen","year":"2012","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clinthera.2015.05.510_bib38","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.05.510_bib39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2377-11-57","article-title":"Tolerability of donepezil 23 mg in moderate to severe Alzheimer\u2019s Disease","volume":"11","author":"Farlow","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clinthera.2015.05.510_bib40","unstructured":"Aricept 23 mg tablets: summary review [FDA Center for Drug Evaluation and Research Application number 022568]. www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022568Orig1s000SumR.pdf. Accessed April 15, 2015"},{"key":"10.1016\/j.clinthera.2015.05.510_bib41","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0b013e3181eb5872","article-title":"Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members","volume":"75","author":"Roberts","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2015.05.510_bib42","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s12603-012-0062-8","article-title":"A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI","volume":"16","author":"Peters","year":"2012","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.clinthera.2015.05.510_bib43","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","article-title":"Vitamin E and donepezil for the treatment of mild cognitive impairment","volume":"352","author":"Petersen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.05.510_bib44","unstructured":"National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease. NICE technology appraisal guidance 217, 2011. http:\/\/guidance.nice.org.uk\/TA217. Accessed April 15, 2015."},{"key":"10.1016\/j.clinthera.2015.05.510_bib45","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1212\/WNL.56.9.1154","article-title":"Practice parameter: management of dementia (an evidence-based review)","volume":"56","author":"Doody","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2015.05.510_bib46","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3122\/jabfm.2012.03.100183","article-title":"Guidelines for the management of cognitive and behavioral problems in dementia","volume":"25","author":"Sadowsky","year":"2012","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.clinthera.2015.05.510_bib47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000122962","article-title":"Treatment options in Alzheimer\u2019s disease: maximizing benefit, managing expectations","volume":"25","author":"Farlow","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.clinthera.2015.05.510_bib48","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1017\/S1041610210001985","article-title":"Switching cholinesterase inhibitors in older adults with dementia","volume":"23","author":"Massoud","year":"2011","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.clinthera.2015.05.510_bib49","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.amjmed.2006.08.036","article-title":"Effective pharmacologic management of Alzheimer\u2019s disease","volume":"120","author":"Farlow","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2015.05.510_bib50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0924-977X(00)00067-5","article-title":"Long-term efficacy and safety of donepezil in the treatment of Alzheimer\u2019s disease: final analysis of a US multicentre open-label study","volume":"10","author":"Rogers","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.clinthera.2015.05.510_bib51","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/archneur.61.2.252","article-title":"The cognitive benefits of galantamine are sustained for at least 36 months: A long-term extension trial","volume":"61","author":"Raskind","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2015.05.510_bib52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2318-5-3","article-title":"ENA713 B352 Study Group. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer\u2019s disease for up to 5 years","volume":"5","author":"Farlow","year":"2005","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.clinthera.2015.05.510_bib53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archneur.63.1.49","article-title":"A 24-week open-label extension study of memantine in moderate to severe Alzheimer\u2019s disease","volume":"63","author":"Reisberg","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2015.05.510_bib54","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archneur.58.3.427","article-title":"Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease","volume":"58","author":"Doody","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2015.05.510_bib55","unstructured":"Discontinuation of cholinesterase inhibitors for the treatment of severe Alzheimer\u2019s disease. [ClinicalTrials.gov; updated Jan 13, 2014]. http:\/\/clinicaltrials.gov\/show\/NCT02035982. Accessed March 19, 2015."},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2015.05.510_bib56","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/alzrt201","article-title":"Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012","volume":"5","author":"Herrmann","year":"2013","journal-title":"Alzheimer Res Ther"},{"issue":"suppl A","key":"10.1016\/j.clinthera.2015.05.510_bib57","first-page":"S9","article-title":"2013; Recommendations for best practices in the treatment of Alzheimer\u2019s disease in managed care","volume":"4","author":"Herrmann","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.clinthera.2015.05.510_bib58","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2010.538083","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer\u2019s disease and other dementias","volume":"12","author":"Ihl","year":"2011","journal-title":"World J Biol Psychiatry"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815008528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815008528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T01:45:51Z","timestamp":1652665551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815008528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0149291815008528"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.05.510","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}